CAMP and interstitial lung disease: Despite that, there are no studies examining BAL levels of LL-37 and lysozyme in ILD patients; LL-37 and lysozyme have been reported to have an anti-fibrotic effect in vitro, reducing proliferation, extracellular matrix, and collagen genes in human fibroblasts [13,25,26].